Skip to main content
. 2021 Oct 6;2(11):100235. doi: 10.1016/j.jtocrr.2021.100235

Figure 3.

Figure 3

Macroscopic illustrations of the (A) right upper lobectomy with ribs and (B) cut surfaces of the formalin-fixed tumor. (C) Immunohistopathologic analysis of the two sections (#.11 and #.18) from the fixed tumor. In the #.11 section, the low-power field (×20) indicates the papillary configuration of the tumor gland and the high-power field (×200) reveals complete loss of SMARCA4 and expression of SMARCA2. PD-L1 TPS is 0%. In the #.18 section, the low-power field indicates the undifferentiated tumor and the high-power field (×200) presents a complete loss of SMARCA4 and SMARCA2. PD-L1 TPS is 0%. The result of the TSO500 panel and the whole-exome sequence of SMARCA2 is summarized in (D). The left column lists the mutated genes with the corresponding amino acid changes. The annotations of OncoKB and COSMIC databases are presented. If the mutation is registered in COSMIC, the COSMIC ID is appended. Heat map of the mutations detected in each sample. #, number; COSMIC, Catalogue Of Somatic Mutations In Cancer; CT, computed tomography; HE, hematoxylin and eosin; ID, identification; LO, likely oncogenic; Mb, Megabase; NA, not annotated; PD-L1, programmed death ligand-1; TMB, tumor mutational burden; TPS, tumor proportion score; U, unknown; VAF, variant allele fraction.